0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Photodynamic Therapy Triggers Cytotoxic Drug Retained to Greater Degree by Cancer Cells

Eric Bernicker
JAMA. 1989;262(18):2500. doi:10.1001/jama.1989.03430180018003.
Text Size: A A A
Published online

ABSTRACT

RESEARCHERS ARE hoping that the triple threat of light, oxygen, and light-sensitive drugs will usher in a new age in cancer treatment. The new weapon, called photodynamic therapy, uses laser light to activate a cytotoxic drug selectively in tumor cells.

The drugs involved, hematoporphyrin and its more potent derivative, dihematoporphyrin ether (DHE, Photofrin) (Quadra Logic Technologies, Vancouver, Canada), have been known to be light activated since early in this century. But it was not until the 1970s that the first systemic use of photodynamic therapy was pioneered by Thomas Dougherty, PhD, and his group at Roswell Park Memorial Institute, the New York State facility in Buffalo.

The drug enters both normal and malignant cells. However, it is retained to a greater degree by neoplastic cells.

Thus, 48 to 72 hours after administration, there is a gradient between the normal cells and the tumor. Photodynamic therapy seeks to exploit this.

The

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();